文献速递临床试验与 GCP基础与转化研究新药、器械与细胞基因治疗研发

同种异体CD19 CAR NK细胞治疗系统性红斑狼疮的疗效与安全性:中国病例系列

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
PubMed 文献 · Lancet · 2025-11-12

这项开放标签、单臂、前瞻性、首次人体病例系列研究纳入18例复发或难治性系统性红斑狼疮成人患者,评估同种异体CD19 CAR NK细胞疗法的安全性、耐受性和疗效。研究未观察到剂量限制性毒性,1例(6%)发生1级细胞因子释放综合征;随访超过12个月的9例患者中6例(67%)达到DORIS缓解和狼疮低疾病活动状态。

要点

  • 18例复发或难治性SLE患者接受同种异体CD19 CAR NK细胞治疗,无剂量限制性毒性。
  • 1例(6%)发生1级细胞因子释放综合征,未观察到神经毒性及其他相关严重不良事件。
  • 随访超过12个月的9例患者中6例(67%)达到DORIS缓解和狼疮低疾病活动状态。

核心结论

  • 本研究提示同种异体CAR NK细胞疗法是治疗自身免疫性疾病的一种有效选择,并提示该疗法可能解决当前自体CAR T细胞疗法在制造规模与时间、可及性、安全性和成本方面的局限。

研究设计与样本

  • 开放标签、单臂、前瞻性、首次人体病例系列研究,在中国一个中心纳入18例年龄18-65岁、既往接受过至少两种标准全身治疗且仍有中重度疾病活动的复发或难治性SLE成人患者。
  • 研究包括方案递增和剂量递增,方案递增从7天开始,剂量递增从第0天0·75×109个CAR NK细胞开始。
  • 所有患者接受氟达拉滨(25 mg/m2每日)和环磷酰胺(300 mg/m2每日)的清淋预处理方案,自第-5天至第-3天每日给药,随后在一个治疗周期内进行三次CAR NK细胞输注,剂量水平相同,输注间隔相同。
  • 患者接受28天剂量限制性不良事件监测;主要终点为安全性和耐受性,包括根据美国国家癌症研究所不良事件通用术语标准5.0版评估的剂量限制性毒性和不良事件发生率。
  • 本研究在ClinicalTrials.gov注册(NCT06010472),随访正在进行中。

主要发现

  • 2023年8月21日至2024年6月16日期间入组18例复发或难治性SLE且疾病活动中重度的患者。
  • 18例患者中17例(94%)为女性;中位年龄37·5岁(IQR 32·0-39·8),中位病程10·5年(IQR 4·5-14·8)。
  • 患者既往接受过至少两种标准全身治疗,其中14例(78%)使用过生物制剂(贝利尤单抗和泰它西普),1例接受过血浆置换。
  • 18例患者中1例(6%)报告细胞因子释放综合征(1级);未观察到神经毒性及其他CAR NK细胞治疗相关严重不良事件,无剂量限制性毒性。
  • 随访超过12个月的9例患者中,6例(67%)达到DORIS缓解和狼疮低疾病活动状态。

关键数值与推荐

  • 剂量递增从第0天0·75×109个CAR NK细胞开始,原文未写明后续剂量递增的具体剂量水平。
  • 预处理方案为氟达拉滨25 mg/m2每日联合环磷酰胺300 mg/m2每日,自第-5天至第-3天每日给药。
  • 一个治疗周期内进行三次CAR NK细胞输注,剂量水平相同,输注间隔相同;原文未写明具体输注间隔天数。
  • 主要终点为安全性和耐受性,包括根据美国国家癌症研究所不良事件通用术语标准5.0版评估的剂量限制性毒性和不良事件发生率。
  • 随访超过12个月的9例患者中6例(67%)达到DORIS缓解和狼疮低疾病活动状态。

临床怎么用

  • 作者认为同种异体CAR NK细胞疗法是治疗自身免疫性疾病的一种有效选择,并提示该疗法可能解决当前自体CAR T细胞疗法在制造规模与时间、可及性、安全性和成本方面的局限。

局限性

  • 本文为开放标签、单臂、首次人体病例系列研究,原文未设对照。
  • 仅有9例患者随访超过12个月,原文报告该9例中6例(67%)达到DORIS缓解和狼疮低疾病活动状态。
  • 原文指出随访正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lately, autologous CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent efficacy in treatment of autoimmune diseases, but with great safety concerns, such as infections. In this study, we aimed to evaluate the safety, tolerability, and efficacy of allogeneic CD19 CAR natural killer (NK)-cell therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE). METHODS: In this open-label, single-arm, prospective, first-in-human case series, we evaluated allogeneic CD19 CAR NK-cell therapy in adult patients (aged 18-65 years) with relapsed or refractory SLE at one site in China. Patients who had received at least two previous standard systemic therapies and continued to exhibit moderate-to-severe disease activity were eligible for inclusion. This study consisted of schedule escalation and dose escalation, with schedule escalation from 7 days and dose escalation commencing at 0·75 × 109 CAR NK cells on day 0. All patients received a lymphodepleting conditioning regimen with fludarabine (25 mg/m2 per day) and cyclophosphamide (300 mg/m2 per day) administered daily from days -5 to -3, followed by three CAR NK-cell infusions within a single treatment cycle at identical dose levels and inter-infusion intervals. Dose-limiting adverse events were monitored in patients for 28 days. The primary endpoints of this study were safety and tolerability, including the incidence of dose-limiting toxicities and adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. This study was registered with ClinicalTrials.gov (NCT06010472) and follow-up is ongoing. FINDINGS: 18 patients with relapsed or refractory SLE with moderate-to-severe disease activity were enrolled between Aug 21, 2023, and June 16, 2024. Of the 18 patients, 17 (94%) were female; the median age was 37·5 years (IQR 32·0-39·8), and the median disease duration was 10·5 years (IQR 4·5-14·8). Patients had received at least two standard systemic therapies, including biological agents (belimumab and telitacicept) in 14 (78%) of 18 patients, and plasmapheresis in one patient. Cytokine release syndrome was reported in one (6%) of 18 patients (grade 1). Neurotoxicity and other CAR NK-cell therapy-related severe adverse events were not observed, and there were no dose-limiting toxicities. Of the nine patients with more than 12 months' follow-up, six (67%) attained DORIS remission and lupus low disease activity state. INTERPRETATION: This study suggests that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and indicates that such a therapy might address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost. FUNDING: Shanghai Municipal Health Commission, Changhai Hospital Affiliated to Naval Medical University, and National Natural Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Gao J, Li M, Sun M, et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet. 2025. PMID: 41240964. doi:10.1016/S0140-6736(25)01671-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。